<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313479839</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313479839</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Viewpoint</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Is there a cure for systemic lupus erythematosus?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Rosario</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479839">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Seguro</surname><given-names>L</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313479839">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Vasconcelos</surname><given-names>C</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479839">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shoenfeld</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff4-0961203313479839">4</xref>
<xref ref-type="corresp" rid="corresp1-0961203313479839"/>
</contrib>
</contrib-group>
<aff id="aff1-0961203313479839"><label>1</label>Internal Medicine Department, Hospital de Pedro Hispano, Portugal</aff>
<aff id="aff2-0961203313479839"><label>2</label>Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Brazil</aff>
<aff id="aff3-0961203313479839"><label>3</label>Unidade de Imunologia Clinica, Hospital Santo Antonio, Portugal</aff>
<aff id="aff4-0961203313479839"><label>4</label>Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center (affiliated with Tel-Aviv University), Israel</aff>
<author-notes>
<corresp id="corresp1-0961203313479839">Yehuda Shoenfeld, Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel. Email: <email>Shoenfel@post.tau.ac.il</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>417</fpage>
<lpage>421</lpage>
<history>
<date date-type="received"><day>26</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>31</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The morbidity and mortality of systemic lupus erythematosus (SLE) is a subject of intense relevance in the literature, yet descriptions of prolonged and sustained remissions or even cure are barely reported.</p>
<p>In recent decades the life expectancy in SLE patients has improved, but the quality of life seems to be poor compared with other chronic diseases and with the general population.</p>
<p>The immunopathogenesis of SLE is complex and not fully understood, so patients have been treated with nonspecific immunosuppressive therapies. But in recent years, because of advances in basic science, targeted therapies have been developed.</p>
<p>Despite the progress made in treating SLE, currently a cure in SLE seems to be a myth. SLE it seems, remains incurable. A specific treatment has not emerged to directly abrogate a disease-specific autoimmune response. Relapsing manifestations and complications of treatment still remain important markers of morbidity.</p>
</abstract>
<kwd-group>
<kwd>Systemic lupus erythematosus</kwd>
<kwd>cure</kwd>
<kwd>sustained remission</kwd>
<kwd>prolonged remission</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313479839" sec-type="intro"><title>Introduction</title>
<p>Systemic lupus erythematosus (SLE) is characterized by a heterogeneity of manifestations and fluctuating disease course with alternating phases of remissions and flares. Its hallmark is the explosion of autoantibodies that can mediate damage in multiple organs.<sup><xref ref-type="bibr" rid="bibr1-0961203313479839">1</xref></sup></p>
<p>The morbidity of SLE has been extensively reported.<sup><xref ref-type="bibr" rid="bibr2-0961203313479839">2</xref><xref ref-type="bibr" rid="bibr3-0961203313479839"/>–<xref ref-type="bibr" rid="bibr4-0961203313479839">4</xref></sup> There are a few sparse reports of prolonged and sustained remissions, but not even one case of a “cure” has so far been reported.</p>
<p>Some autoimmune diseases are known to be “curable,” yet, will we be able to achieve a cure for SLE in the near future?</p>
</sec>
<sec id="sec2-0961203313479839"><title>“Curable” autoimmune diseases</title>
<p>There are some autoimmune diseases that are curable. The prototype of curable autoimmune disease is drug-induced lupus, in which the discontinuation of the drug induces a cure.<sup><xref ref-type="bibr" rid="bibr5-0961203313479839">5</xref></sup> There are a number of autoimmune disorders associated with <italic>Helicobacter Pylori</italic> (<italic>H. pylori</italic>) infection such as idiopathic thrombocytopenic purpura,<sup><xref ref-type="bibr" rid="bibr6-0961203313479839">6</xref>,<xref ref-type="bibr" rid="bibr7-0961203313479839">7</xref></sup> autoimmune thyroiditis,<sup><xref ref-type="bibr" rid="bibr8-0961203313479839">8</xref>,<xref ref-type="bibr" rid="bibr9-0961203313479839">9</xref></sup> Sjögren’s syndrome,<sup><xref ref-type="bibr" rid="bibr10-0961203313479839">10</xref>,<xref ref-type="bibr" rid="bibr11-0961203313479839">11</xref></sup> Behcet's disease<sup><xref ref-type="bibr" rid="bibr12-0961203313479839">12</xref></sup> and psoriasis,<sup><xref ref-type="bibr" rid="bibr13-0961203313479839">13</xref>,<xref ref-type="bibr" rid="bibr14-0961203313479839">14</xref></sup> in which remission can be induced after the eradication of the <italic>H. pylori</italic> infection.<sup><xref ref-type="bibr" rid="bibr12-0961203313479839">12</xref>,<xref ref-type="bibr" rid="bibr14-0961203313479839">14</xref>,<xref ref-type="bibr" rid="bibr15-0961203313479839">15</xref></sup> Another example of a curable autoimmune disease is celiac disease, in which adherence to a lifelong strict gluten-free diet leads to a “cure.”<sup><xref ref-type="bibr" rid="bibr16-0961203313479839">16</xref></sup></p>
</sec>
<sec id="sec3-0961203313479839"><title>Definitions of remission, prolonged remission and a cure in SLE</title>
<p>In recent decades the treatment and life expectancy of SLE patients have been significantly improved.<sup><xref ref-type="bibr" rid="bibr2-0961203313479839">2</xref>,<xref ref-type="bibr" rid="bibr4-0961203313479839">4</xref>,<xref ref-type="bibr" rid="bibr17-0961203313479839">17</xref>,<xref ref-type="bibr" rid="bibr18-0961203313479839">18</xref></sup> Despite that, evidence suggests that the quality of this extended life can remain poor compared with that of the general population and worse than that of individuals with other chronic diseases.<sup><xref ref-type="bibr" rid="bibr19-0961203313479839">19</xref>,<xref ref-type="bibr" rid="bibr20-0961203313479839">20</xref></sup></p>
<p>In the majority of patients the disease is no longer an acute life-threatening disease but a chronic one. This notion of “chronic disease” relies on the fact that, with time, clinical experience shows that it progresses in a relapsing way. This in fact is contradictory to the definition of a cure. The evolution of novel and more specific therapies in SLE might possibly lead to a change in this point of view.</p>
<p>Many indices of disease activity have been developed.<sup><xref ref-type="bibr" rid="bibr21-0961203313479839">21</xref><xref ref-type="bibr" rid="bibr22-0961203313479839"/><xref ref-type="bibr" rid="bibr23-0961203313479839"/>–<xref ref-type="bibr" rid="bibr24-0961203313479839">24</xref></sup> They present definitions for flares and response to therapy, yet there are no uniform acceptable criteria for the definition of a disease remission. Most authors agree that the concept of disease remission should include patients without clinical signs of activity and those who are not under any therapy. Yet the relevance of serological activity varies in these definitions.<sup><xref ref-type="bibr" rid="bibr25-0961203313479839">25</xref><xref ref-type="bibr" rid="bibr26-0961203313479839"/><xref ref-type="bibr" rid="bibr27-0961203313479839"/><xref ref-type="bibr" rid="bibr28-0961203313479839"/>–<xref ref-type="bibr" rid="bibr29-0961203313479839">29</xref></sup> Schneider<sup><xref ref-type="bibr" rid="bibr30-0961203313479839">30</xref></sup> proposed that a complete remission should be considered in the absence of any clinically obvious disease activity with normal levels of activity markers. He used this definition in analogy to the oncologic definition, which considers a complete remission as a disappearance of all known clinical disease parameters with normalization of biochemical tumor markers. Additionally he refers to “partial remission” in cases of clinical remission with an incomplete response in laboratory parameters. The patients without clinical activity but with persistent serological markers are referred to in the literature as “serologically active clinically quiescent patients”.<sup><xref ref-type="bibr" rid="bibr31-0961203313479839">31</xref><xref ref-type="bibr" rid="bibr32-0961203313479839"/>–<xref ref-type="bibr" rid="bibr33-0961203313479839">33</xref></sup> These definitions are very important when we compare the results of different prospective studies.</p>
<p>Urowitz et al.<sup><xref ref-type="bibr" rid="bibr25-0961203313479839">25</xref></sup> concluded that a complete remission in SLE is rare; only 12 out of 703 SLE patients (1.7%) had a prolonged complete remission after five years without therapy. In this same cohort at one year of follow-up, only 6.5% patients achieved complete remission. These results were in contradiction to previous studies,<sup><xref ref-type="bibr" rid="bibr28-0961203313479839">28</xref>,<xref ref-type="bibr" rid="bibr29-0961203313479839">29</xref></sup> mainly because the definition used in those studies was not as stringent as the one applied by Urowitz et al.,<sup><xref ref-type="bibr" rid="bibr25-0961203313479839">25</xref></sup> and included a duration of five disease-free years.</p>
<p>Uniformity is difficult in these definitions. For instance, autoantibodies may be present in the normal population.<sup><xref ref-type="bibr" rid="bibr34-0961203313479839">34</xref></sup> Thus, it is possible to consider a patient who lost his or her anti-double-stranded DNA (anti-dsDNA) but maintained antinuclear antibodies (ANA) as having a complete remission. Furthermore, it is also important to mention that, in contrast to other classical autoimmune diseases, the autoantigens in SLE are still unknown. The disease is characterized by a large number of autoantibodies and it has not been determined which ones are pathogenic in SLE and which ones are an epiphenomenon.<sup><xref ref-type="bibr" rid="bibr1-0961203313479839">1</xref></sup></p>
</sec>
<sec id="sec4-0961203313479839"><title>Duration of the remission</title>
<p>Another important point is the duration of the remission; if SLE is known to progress with remissions and flares, can we say that an SLE patient will be ever cured? When should we consider a long-term remission? After five or 10 years of complete remission?</p>
<p>There are few reports of a “long sustained remission” in SLE patients, though undoubtedly most large lupus clinics have such cases. One was reported in 1999 by Mittal et al<italic>.</italic><sup><xref ref-type="bibr" rid="bibr35-0961203313479839">35</xref></sup> of eight years of complete remission after accidental administration of a single dose of 5 g of intravenous cyclophosphamide. Rossi et al<italic>.</italic><sup><xref ref-type="bibr" rid="bibr36-0961203313479839">36</xref></sup> in 2011 reported a series of six SLE patients who developed malignant lymphomas and were treated with high-dose chemotherapy. Of those patients, one achieved a complete remission of both diseases in a follow-up of four years, one patient had a relapse of both diseases and in the others remission was achieved only for the lymphoma with relapse of the SLE.</p>
<p>In 2001, Moroni et al.<sup><xref ref-type="bibr" rid="bibr37-0961203313479839">37</xref></sup> described a case of a patient with lupus nephritis who achieved a complete remission for 14 years after treatment with prednisone and cyclophosphamide. Later on she had evidence of serological activity without any clinical manifestation and, nine years later, developed a nephritic flare-up.</p>
<p>Some SLE patients who underwent hematopoietic stem cell transplantation achieved long-term, treatment-free remissions, but this result is not universal and most of the patients required maintenance therapy, as discussed below.<sup><xref ref-type="bibr" rid="bibr38-0961203313479839">38</xref><xref ref-type="bibr" rid="bibr39-0961203313479839"/>–<xref ref-type="bibr" rid="bibr40-0961203313479839">40</xref></sup></p>
</sec>
<sec id="sec5-0961203313479839"><title>Emerging therapies for SLE</title>
<p>The manifestations in SLE vary between patients, and in the same patient different symptoms may occur in subsequent flares. Therefore the choice of treatment depends on various factors (e.g. organ involvement, tolerability, severity, comorbidities).</p>
<p>The immunopathogenesis of SLE is complex and not fully understood.<sup><xref ref-type="bibr" rid="bibr41-0961203313479839">41</xref><xref ref-type="bibr" rid="bibr42-0961203313479839"/>–<xref ref-type="bibr" rid="bibr43-0961203313479839">43</xref></sup> Patients have been treated with nonspecific immunosuppressive therapies, resulting in significant toxicities and side effects.</p>
<p>In recent years, targeted therapies were developed for SLE.<sup><xref ref-type="bibr" rid="bibr43-0961203313479839">43</xref><xref ref-type="bibr" rid="bibr44-0961203313479839"/><xref ref-type="bibr" rid="bibr45-0961203313479839"/>–<xref ref-type="bibr" rid="bibr46-0961203313479839">46</xref></sup> One of these therapies relies on B-cell depletion, since B-cell hyperactivity is a major pathogenic mechanism for SLE. B-cell depletion employing anti-CD20 antibody rituximab in refractory SLE has shown a rapid onset of effect, but the durability of efficacy relies on the efficiency of the depletion phase and the timing of reconstitution of the pathogenic clones. Repopulation of B cells implies repeated courses of therapy with an increased risk of hypogammaglobulinemia and infection. Also, a potential problem is reduced efficacy due to tolerance to the drug. The majority of these studies had a short follow-up period and the clinical improvement was not accompanied by a laboratory remission.<sup><xref ref-type="bibr" rid="bibr44-0961203313479839">44</xref>,<xref ref-type="bibr" rid="bibr47-0961203313479839">47</xref>,<xref ref-type="bibr" rid="bibr48-0961203313479839">48</xref></sup></p>
<p>New advances in the treatment of SLE are in development, and several biological agents for SLE patients are currently being investigated in clinical trials.<sup><xref ref-type="bibr" rid="bibr44-0961203313479839">44</xref><xref ref-type="bibr" rid="bibr45-0961203313479839"/>–<xref ref-type="bibr" rid="bibr46-0961203313479839">46</xref></sup> Recently several artificial peptides were generated that have the ability to induce immunological tolerance. These toleragenic peptides were shown to protect the target organs from antibody-mediated damage in mice. They are being postulated as the future treatment for autoimmune diseases without major side effects.<sup><xref ref-type="bibr" rid="bibr49-0961203313479839">49</xref><xref ref-type="bibr" rid="bibr50-0961203313479839"/><xref ref-type="bibr" rid="bibr51-0961203313479839"/>–<xref ref-type="bibr" rid="bibr52-0961203313479839">52</xref></sup></p>
<p>Hematopoietic stem cell transplantation (HSCT) was claimed to “cure” severe autoimmune diseases. Since 1997 approximately 200 autologous HSCTs have been reported for SLE. In 2011 Illei et al. reviewed autologous HSCT in SLE patients and reported a probability of a five-year disease free-survival between 50% and 70%; however, this goal was associated with an increase of short-term mortality.<sup><xref ref-type="bibr" rid="bibr40-0961203313479839">40</xref></sup> The European Group for Bone Marrow Transplantation registry reported that the 100-day mortality was 11%, the overall five-year survival was 76% and progression-free survival at five years was 44% (<italic>n</italic> = 85).<sup><xref ref-type="bibr" rid="bibr53-0961203313479839">53</xref>,<xref ref-type="bibr" rid="bibr54-0961203313479839">54</xref></sup> An interesting complication following HSCT, both autologous and allogeneic, is the occurrence of secondary autoimmune diseases.<sup><xref ref-type="bibr" rid="bibr55-0961203313479839">55</xref><xref ref-type="bibr" rid="bibr56-0961203313479839"/>–<xref ref-type="bibr" rid="bibr57-0961203313479839">57</xref></sup> SLE is the autoimmune disease most liable to develop after autologous HSCT transplant.<sup><xref ref-type="bibr" rid="bibr39-0961203313479839">39</xref></sup> Remarkable also are the reported cases by Rossi et al.<sup><xref ref-type="bibr" rid="bibr36-0961203313479839">36</xref></sup> of patients with malignant B lymphomas in whom high-dose chemotherapy eradicated the malignancy but not the SLE. While a complete cure of cancer can be obtained by eradication of the last cancer cell, autoimmunity maintains its refractoriness. Relapses of autoimmune diseases have also been reported even after a more powerful procedure of allotransplantation.<sup><xref ref-type="bibr" rid="bibr58-0961203313479839">58</xref><xref ref-type="bibr" rid="bibr59-0961203313479839"/>–<xref ref-type="bibr" rid="bibr60-0961203313479839">60</xref></sup></p>
<p>HSCT for autoimmune therapy should not be seen as a curative therapy but rather as inducing a change in the natural history of the disease. The idea of obtaining stable complete remissions is not yet realistic. Although it is possible that some patients may achieve complete remission (as clinical remission, normalization of autoimmune markers and freedom from drug therapy) for the follow-up of five to seven years, the majority need maintenance therapy.<sup><xref ref-type="bibr" rid="bibr38-0961203313479839">38</xref><xref ref-type="bibr" rid="bibr39-0961203313479839"/>–<xref ref-type="bibr" rid="bibr40-0961203313479839">40</xref></sup> Currently, allogenic HSCT for SLE patients seems to be indicated only for cases with disease complicated by an oncohematologic malignancy. Autologous HSCT is being used as a salvage therapy for otherwise intractable SLE patients.<sup><xref ref-type="bibr" rid="bibr39-0961203313479839">39</xref></sup></p>
<p>Despite the emergence of targeted therapies in SLE, the results are quite disappointing.</p>
</sec>
<sec id="sec6-0961203313479839" sec-type="conclusions"><title>Conclusions</title>
<p>Presently, despite the improved outcome in SLE patients over the last few years, a cure seems elusive. We may say that SLE remains incurable insomuch as a specific treatment has not emerged to directly abrogate the disease-specific autoimmune reactions. Relapsing manifestations and complications of past treatments still remain important markers of morbidity.</p>
<p>New treatments, more specific and less immunosuppressive, are being explored to tackle autoimmunity; they are aimed at eliminating the existing pathogenic clones and the induction of immune tolerance through resetting or regulating the immune system.</p>
<p>With the evolution in basic science and better knowledge of the complex pathophysiology of SLE, it may, in the future, lead to a cure. It will probably involve combining different therapies that are addressed to eradicate not just the aberrant autodestructive immune system but also to target “specific” autoantigens.</p>
</sec>
</body>
<back>
<sec id="sec7-0961203313479839"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec8-0961203313479839"><title>Conflict of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313479839"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sherer</surname><given-names>Y</given-names></name><name><surname>Gorstein</surname><given-names>A</given-names></name><name><surname>Fritzler</surname><given-names>MJ</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Autoantibody explosion in systemic lupus erythematosus: More than 100 different antibodies found in SLE patients</article-title>. <source>Semin Arthritis Rheum</source> <year>2004</year>; <volume>34</volume>: <fpage>501</fpage>–<lpage>537</lpage>.</citation></ref>
<ref id="bibr2-0961203313479839"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Borchers</surname><given-names>AT</given-names></name><name><surname>Keen</surname><given-names>CL</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Surviving the butterfly and the wolf: Mortality trends in systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2004</year>; <volume>3</volume>: <fpage>423</fpage>–<lpage>453</lpage>.</citation></ref>
<ref id="bibr3-0961203313479839"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Morbidity in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1987</year>; <volume>14</volume>: <fpage>223</fpage>–<lpage>226</lpage>.</citation></ref>
<ref id="bibr4-0961203313479839"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Khamashta</surname><given-names>MA</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients</article-title>. <source>Medicine (Baltimore)</source> <year>2003</year>; <volume>82</volume>: <fpage>299</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr5-0961203313479839"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>U</given-names></name><name><surname>Zandman-Goddard</surname><given-names>G</given-names></name></person-group>. <article-title>Drug-induced lupus: An update</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>10</volume>: <fpage>46</fpage>–<lpage>50</lpage>.</citation></ref>
<ref id="bibr6-0961203313479839"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campuzano-Maya</surname><given-names>G</given-names></name></person-group>. <article-title>Proof of an association between Helicobacter pylori and idiopathic thrombocytopenic purpura in Latin America</article-title>. <source>Helicobacter</source> <year>2007</year>; <volume>2</volume>: <fpage>265</fpage>–<lpage>273</lpage>.</citation></ref>
<ref id="bibr7-0961203313479839"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stasi</surname><given-names>R</given-names></name><name><surname>Sarpatwari</surname><given-names>A</given-names></name><name><surname>Segal</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: A systematic review</article-title>. <source>Blood</source> <year>2009</year>; <volume>113</volume>: <fpage>1231</fpage>–<lpage>1240</lpage>.</citation></ref>
<ref id="bibr8-0961203313479839"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Luis</surname><given-names>DA</given-names></name><name><surname>Varela</surname><given-names>C</given-names></name><name><surname>De La Calle</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Helicobacter pylori infection is markedly increased in patients with autoimmune atrophic thyroiditis</article-title>. <source>J Clin Gastroenterol</source> <year>1998</year>; <volume>26</volume>: <fpage>259</fpage>–<lpage>263</lpage>.</citation></ref>
<ref id="bibr9-0961203313479839"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franceschi</surname><given-names>F</given-names></name><name><surname>Satta</surname><given-names>MA</given-names></name><name><surname>Mentella</surname><given-names>MC</given-names></name><etal/></person-group>. <article-title>Helicobacter pylori infection in patients with Hashimoto’s thyroiditis</article-title>. <source>Helicobacter</source> <year>2004</year>; <volume>9</volume>: <fpage>369</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr10-0961203313479839"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aragona</surname><given-names>P</given-names></name><name><surname>Magazzù</surname><given-names>G</given-names></name><name><surname>Macchia</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Presence of antibodies against Helicobacter pylori and its heat-shock protein 60 in the serum of patients with Sjögren’s syndrome</article-title>. <source>J Rheumatol</source> <year>1999</year>; <volume>26</volume>: <fpage>1306</fpage>–<lpage>1311</lpage>.</citation></ref>
<ref id="bibr11-0961203313479839"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sorrentino</surname><given-names>D</given-names></name><name><surname>Faller</surname><given-names>G</given-names></name><name><surname>DeVita</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Helicobacter pylori associated antigastric autoantibodies: Role in Sjögren’s syndrome gastritis</article-title>. <source>Helicobacter</source> <year>2004</year>; <volume>9</volume>: <fpage>46</fpage>–<lpage>53</lpage>.</citation></ref>
<ref id="bibr12-0961203313479839"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Avci</surname><given-names>O</given-names></name><name><surname>Ellidokuz</surname><given-names>E</given-names></name><name><surname>Simsek</surname><given-names>I</given-names></name><name><surname>Buyukgebiz</surname><given-names>B</given-names></name><name><surname>Gunes</surname><given-names>AT</given-names></name></person-group>. <article-title>Helicobacter pylori and Behcet’s disease</article-title>. <source>Dermatology</source> <year>1999</year>; <volume>199</volume>: <fpage>140</fpage>–<lpage>143</lpage>.</citation></ref>
<ref id="bibr13-0961203313479839"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>M</given-names></name><name><surname>Whitehead</surname><given-names>M</given-names></name></person-group>. <article-title>Clearance of chronic psoriasis after eradication therapy for Helicobacter pylori infection</article-title>. <source>J Eur Acad Dermatol Venereol</source> <year>2008</year>; <volume>22</volume>: <fpage>753</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr14-0961203313479839"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martin Hübner</surname><given-names>A</given-names></name><name><surname>Tenbaum</surname><given-names>SP</given-names></name></person-group>. <article-title>Complete remission of palmoplantar psoriasis through Helicobacter pylori eradication: A case report</article-title>. <source>Clin Exp Dermatol</source> <year>2008</year>; <volume>33</volume>: <fpage>339</fpage>–<lpage>340</lpage>.</citation></ref>
<ref id="bibr15-0961203313479839"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kikuchi</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Sakamaki</surname><given-names>H</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name></person-group>. <article-title>Eight-year follow-up of patients with immune thrombocytopenic purpura related to H. <italic>pylori</italic> infection</article-title>. <source>Platelets</source> <year>2011</year>; <volume>22</volume>: <fpage>61</fpage>–<lpage>64</lpage>.</citation></ref>
<ref id="bibr16-0961203313479839"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mubarak</surname><given-names>A</given-names></name><name><surname>Houwen</surname><given-names>RH</given-names></name><name><surname>Wolters</surname><given-names>VM</given-names></name></person-group>. <article-title>Celiac disease: An overview from pathophysiology to treatment</article-title>. <source>Minerva Pediatr</source> <year>2012</year>; <volume>64</volume>: <fpage>271</fpage>–<lpage>287</lpage>.</citation></ref>
<ref id="bibr17-0961203313479839"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uramoto</surname><given-names>KM</given-names></name><name><surname>Michet</surname><given-names>CJ</given-names><suffix>Jr</suffix></name><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Sunku</surname><given-names>J</given-names></name><name><surname>O’Fallon</surname><given-names>WM</given-names></name><name><surname>Gabriel</surname><given-names>SE</given-names></name></person-group>. <article-title>Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992</article-title>. <source>Arthritis Rheum</source> <year>1999</year>; <volume>42</volume>: <fpage>46</fpage>–<lpage>50</lpage>.</citation></ref>
<ref id="bibr18-0961203313479839"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Halberg</surname><given-names>P</given-names></name><name><surname>Alsbjorn</surname><given-names>B</given-names></name><name><surname>Balslov</surname><given-names>JT</given-names></name><etal/></person-group>. <article-title>Systemic lupus erythematosus: follow-up study of 148 patients: I. Classification, clinical and laboratory findings, course and outcome</article-title>. <source>Clin Rheumatol</source> <year>1987</year>; <volume>6</volume>: <fpage>13</fpage>–<lpage>21</lpage>.</citation></ref>
<ref id="bibr19-0961203313479839"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jolly</surname><given-names>M</given-names></name></person-group>. <article-title>How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses?</article-title> <source>J Rheumatol</source> <year>2005</year>; <volume>32</volume>: <fpage>1706</fpage>–<lpage>1708</lpage>.</citation></ref>
<ref id="bibr20-0961203313479839"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thumboo</surname><given-names>J</given-names></name><name><surname>Strand</surname><given-names>V</given-names></name></person-group>. <article-title>Health-related quality of life in patients with systemic lupus erythematosus: An update</article-title>. <source>Ann Acad Med Singapore</source> <year>2007</year>; <volume>36</volume>: <fpage>115</fpage>–<lpage>122</lpage>.</citation></ref>
<ref id="bibr21-0961203313479839"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lam</surname><given-names>GK</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>. <article-title>Assessment of systemic lupus erythematosus</article-title>. <source>Clin Exp Rheumatol</source> <year>2005</year>; <volume>23</volume>: <fpage>S120</fpage>–<lpage>S132</lpage>.</citation></ref>
<ref id="bibr22-0961203313479839"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Luijten</surname><given-names>KM</given-names></name><name><surname>Tekstra</surname><given-names>J</given-names></name><name><surname>Bijlsma</surname><given-names>JW</given-names></name><name><surname>Bijl</surname><given-names>M</given-names></name></person-group>. <article-title>The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment</article-title>. <source>Autoimmun Rev</source> <year>2012</year>; <volume>11</volume>: <fpage>326</fpage>–<lpage>329</lpage>.</citation></ref>
<ref id="bibr23-0961203313479839"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>B</given-names></name><name><surname>Mosca</surname><given-names>M</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name></person-group>. <article-title>Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices</article-title>. <source>Best Pract Res Clin Rheumatol</source> <year>2005</year>; <volume>19</volume>: <fpage>685</fpage>–<lpage>708</lpage>.</citation></ref>
<ref id="bibr24-0961203313479839"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Kagal</surname><given-names>A</given-names></name><name><surname>Hallett</surname><given-names>D</given-names></name></person-group>. <article-title>Accurately describing changes in disease activity in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>377</fpage>–<lpage>379</lpage>.</citation></ref>
<ref id="bibr25-0961203313479839"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Feletar</surname><given-names>M</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>Ibañez</surname><given-names>D</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name></person-group>. <article-title>Prolonged remission in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>2005</year>; <volume>32</volume>: <fpage>1467</fpage>–<lpage>1472</lpage>.</citation></ref>
<ref id="bibr26-0961203313479839"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tozman</surname><given-names>ECS</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name></person-group>. <article-title>Prolonged complete remission in previously severe SLE</article-title>. <source>Ann Rheum Dis</source> <year>1982</year>; <volume>41</volume>: <fpage>39</fpage>–<lpage>40</lpage>.</citation></ref>
<ref id="bibr27-0961203313479839"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drenkard</surname><given-names>C</given-names></name><name><surname>Villa</surname><given-names>AR</given-names></name><name><surname>Garcia-Padilla</surname><given-names>C</given-names></name><name><surname>Pérez-Vázquez</surname><given-names>ME</given-names></name><name><surname>Alarcón-Segovia</surname><given-names>D</given-names></name></person-group>. <article-title>Remission of systemic lupus erythematosus</article-title>. <source>Medicine (Baltimore)</source> <year>1996</year>; <volume>75</volume>: <fpage>88</fpage>–<lpage>98</lpage>.</citation></ref>
<ref id="bibr28-0961203313479839"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Formiga</surname><given-names>F</given-names></name><name><surname>Moga</surname><given-names>I</given-names></name><name><surname>Pac</surname><given-names>M</given-names></name><name><surname>Mitjavila</surname><given-names>F</given-names></name><name><surname>Rivera</surname><given-names>A</given-names></name><name><surname>Pujol</surname><given-names>R</given-names></name></person-group>. <article-title>High disease activity at baseline does not prevent a remission in patients with systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <year>1999</year>; <volume>38</volume>: <fpage>724</fpage>–<lpage>727</lpage>.</citation></ref>
<ref id="bibr29-0961203313479839"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>CA</given-names></name><name><surname>Schur</surname><given-names>PH</given-names></name></person-group>. <article-title>Serological and clinical remission in systemic lupus erythematosus</article-title>. <source>J Rheumatol</source> <year>1985</year>; <volume>12</volume>: <fpage>916</fpage>–<lpage>918</lpage>.</citation></ref>
<ref id="bibr30-0961203313479839"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>M</given-names></name></person-group>. <article-title>Response and remission criteria for clinical trials in lupus: What can we learn from other diseases?</article-title> <source>Lupus</source> <year>1999</year>; <volume>8</volume>: <fpage>627</fpage>–<lpage>631</lpage>.</citation></ref>
<ref id="bibr31-0961203313479839"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Steiman</surname><given-names>AJ</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibañez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Prolonged serologically active clinically quiescent systemic lupus erythematosus: Frequency and outcome</article-title>. <source>J Rheumatol</source> <year>2010</year>; <volume>37</volume>: <fpage>1822</fpage>–<lpage>1827</lpage>.</citation></ref>
<ref id="bibr32-0961203313479839"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Keystone</surname><given-names>EC</given-names></name></person-group>. <article-title>Serologically active clinically quiescent systemic lupus erythematosus: A discordance between clinical and serologic features</article-title>. <source>Am J Med</source> <year>1979</year>; <volume>66</volume>: <fpage>210</fpage>–<lpage>215</lpage>.</citation></ref>
<ref id="bibr33-0961203313479839"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Walz LeBlanc</surname><given-names>BA</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Serologically active clinically quiescent systemic lupus erythematosus — predictors of clinical flares</article-title>. <source>J Rheumatol</source> <year>1994</year>; <volume>21</volume>: <fpage>2239</fpage>–<lpage>2241</lpage>.</citation></ref>
<ref id="bibr34-0961203313479839"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yadin</surname><given-names>O</given-names></name><name><surname>Sarov</surname><given-names>B</given-names></name><name><surname>Naggan</surname><given-names>L</given-names></name><name><surname>Slor</surname><given-names>H</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>Natural autoantibodies in the serum of healthy women — a five-year follow-up</article-title>. <source>Clin Exp Immunol</source> <year>1989</year>; <volume>75</volume>: <fpage>402</fpage>–<lpage>406</lpage>.</citation></ref>
<ref id="bibr35-0961203313479839"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname><given-names>G</given-names></name><name><surname>Balakrishna</surname><given-names>C</given-names></name><name><surname>Mangat</surname><given-names>G</given-names></name><name><surname>Joshi</surname><given-names>VR</given-names></name></person-group>. <article-title>“Sustained remission” in a case of SLE following megadose cyclophosphamide</article-title>. <source>Lupus</source> <year>1999</year>; <volume>8</volume>: <fpage>77</fpage>–<lpage>80</lpage>.</citation></ref>
<ref id="bibr36-0961203313479839"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>E</given-names></name><name><surname>Catania</surname><given-names>G</given-names></name><name><surname>Truini</surname><given-names>M</given-names></name><name><surname>Ravetti</surname><given-names>GL</given-names></name><name><surname>Grassia</surname><given-names>L</given-names></name><name><surname>Marmont</surname><given-names>AM</given-names></name></person-group>. <article-title>Patients with systemic lupus erythematosus (SLE) having developed malignant lymphomas. Complete remission of lymphoma following high-dose chemotherapy, but not of SLE</article-title>. <source>Clin Exp Rheumatol</source> <year>2011</year>; <volume>29</volume>: <fpage>555</fpage>–<lpage>559</lpage>.</citation></ref>
<ref id="bibr37-0961203313479839"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moroni</surname><given-names>G</given-names></name><name><surname>Greloni</surname><given-names>GC</given-names></name><name><surname>Ponticelli</surname><given-names>C</given-names></name></person-group>. <article-title>Late recurrence of lupus nephritis after long-term clinical remission</article-title>. <source>Nephrol Dial Transplant</source> <year>2001</year>; <volume>16</volume>: <fpage>849</fpage>–<lpage>852</lpage>.</citation></ref>
<ref id="bibr38-0961203313479839"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burt</surname><given-names>RK</given-names></name><name><surname>Testori</surname><given-names>A</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>B</given-names></name><name><surname>Suffit</surname><given-names>R</given-names></name><name><surname>Barr</surname><given-names>W</given-names></name></person-group>. <article-title>Hematopoietic stem cell transplantation for autoimmune diseases: What have we learned?</article-title> <source>J Autoimmun</source> <year>2008</year>; <volume>30</volume>: <fpage>116</fpage>–<lpage>120</lpage>.</citation></ref>
<ref id="bibr39-0961203313479839"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marmont</surname><given-names>AM</given-names></name></person-group>. <article-title>Hematopoietic stem cell transplantation for systemic lupus erythematosus</article-title>. <source>Clin Dev Immunol</source> <year>2012</year>; <volume>2012</volume>: <fpage>380391</fpage>–<lpage>380391</lpage>.</citation></ref>
<ref id="bibr40-0961203313479839"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Burt</surname><given-names>RK</given-names></name><etal/></person-group>. <article-title>Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus</article-title>. <source>Ann Rheum Dis</source> <year>2011</year>; <volume>70</volume>: <fpage>2071</fpage>–<lpage>2074</lpage>.</citation></ref>
<ref id="bibr41-0961203313479839"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gualtierotti</surname><given-names>R</given-names></name><name><surname>Biggioggero</surname><given-names>M</given-names></name><name><surname>Penatti</surname><given-names>AE</given-names></name><name><surname>Meroni</surname><given-names>PL</given-names></name></person-group>. <article-title>Updating on the pathogenesis of systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>10</volume>: <fpage>3</fpage>–<lpage>7</lpage>.</citation></ref>
<ref id="bibr42-0961203313479839"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muñoz</surname><given-names>LE</given-names></name><name><surname>Janko</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Autoimmunity and chronic inflammation — two clearance-related steps in the etiopathogenesis of SLE</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>10</volume>: <fpage>38</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr43-0961203313479839"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsokos</surname><given-names>GC</given-names></name></person-group>. <article-title>Systemic lupus erythematosus</article-title>. <source>N Engl J Med</source> <year>2011</year>; <volume>365</volume>: <fpage>2110</fpage>–<lpage>2121</lpage>.</citation></ref>
<ref id="bibr44-0961203313479839"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name></person-group>. <article-title>Update on emerging drug therapies for systemic lupus erythematosus</article-title>. <source>Expert Opin Emerg Drugs</source> <year>2010</year>; <volume>15</volume>: <fpage>53</fpage>–<lpage>70</lpage>.</citation></ref>
<ref id="bibr45-0961203313479839"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bezalel</surname><given-names>S</given-names></name><name><surname>Asher</surname><given-names>I</given-names></name><name><surname>Elbirt</surname><given-names>D</given-names></name><name><surname>Sthoeger</surname><given-names>ZM</given-names></name></person-group>. <article-title>Novel biological treatments for systemic lupus erythematosus: Current and future modalities</article-title>. <source>Isr Med Assoc J</source> <year>2012</year>; <volume>14</volume>: <fpage>508</fpage>–<lpage>514</lpage>.</citation></ref>
<ref id="bibr46-0961203313479839"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murdaca</surname><given-names>G</given-names></name><name><surname>Colombo</surname><given-names>BM</given-names></name><name><surname>Puppo</surname><given-names>F</given-names></name></person-group>. <article-title>Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events</article-title>. <source>Autoimmun Rev</source> <year>2011</year>; <volume>11</volume>: <fpage>56</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr47-0961203313479839"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>KG</given-names></name><name><surname>Jones</surname><given-names>RB</given-names></name><name><surname>Burns</surname><given-names>SM</given-names></name><name><surname>Jayne</surname><given-names>DR</given-names></name></person-group>. <article-title>Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2970</fpage>–<lpage>2982</lpage>.</citation></ref>
<ref id="bibr48-0961203313479839"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Vollenhoven</surname><given-names>RF</given-names></name></person-group>. <article-title>Rituximab — shadow, illusion or light?</article-title> <source>Autoimmun Rev</source> <year>2012</year>; <volume>11</volume>: <fpage>563</fpage>–<lpage>567</lpage>.</citation></ref>
<ref id="bibr49-0961203313479839"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>Singh</surname><given-names>RR</given-names></name><name><surname>Wong</surname><given-names>WK</given-names></name><name><surname>Tsao</surname><given-names>BP</given-names></name><name><surname>Bulpitt</surname><given-names>K</given-names></name><name><surname>Ebling</surname><given-names>FM</given-names></name></person-group>. <article-title>Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus</article-title>. <source>Arthritis Rheum</source> <year>2001</year>; <volume>44</volume>: <fpage>432</fpage>–<lpage>441</lpage>.</citation></ref>
<ref id="bibr50-0961203313479839"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Monneaux</surname><given-names>F</given-names></name><name><surname>Schall</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: Results of an early phase II clinical trial</article-title>. <source>Arthritis Rheum</source> <year>2008</year>; <volume>58</volume>: <fpage>3873</fpage>–<lpage>3883</lpage>.</citation></ref>
<ref id="bibr51-0961203313479839"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mozes</surname><given-names>E</given-names></name><name><surname>Sharabi</surname><given-names>A</given-names></name></person-group>. <article-title>A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>10</volume>: <fpage>22</fpage>–<lpage>26</lpage>.</citation></ref>
<ref id="bibr52-0961203313479839"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>B</given-names></name><name><surname>Bloom</surname><given-names>O</given-names></name><name><surname>Al Abed</surname><given-names>Y</given-names></name><name><surname>Kowal</surname><given-names>C</given-names></name><name><surname>Huerta</surname><given-names>PT</given-names></name><name><surname>Volpe</surname><given-names>BT</given-names></name></person-group>. <article-title>Moving towards a cure: Blocking pathogenic antibodies in systemic lupus erythematosus</article-title>. <source>J Intern Med</source> <year>2011</year>; <volume>269</volume>: <fpage>36</fpage>–<lpage>44</lpage>.</citation></ref>
<ref id="bibr53-0961203313479839"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jayne</surname><given-names>D</given-names></name><name><surname>Passweg</surname><given-names>J</given-names></name></person-group>. <article-title>Autologous stem cell transplantation for systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2004</year>; <volume>13</volume>: <fpage>168</fpage>–<lpage>176</lpage>.</citation></ref>
<ref id="bibr54-0961203313479839"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farge</surname><given-names>D</given-names></name><name><surname>Labopin</surname><given-names>M</given-names></name><name><surname>Tyndall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Autologous hematopoietic stem cell transplantation for autoimmune diseases: An observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases</article-title>. <source>Haematologica</source> <year>2010</year>; <volume>95</volume>: <fpage>284</fpage>–<lpage>292</lpage>.</citation></ref>
<ref id="bibr55-0961203313479839"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Daikeler</surname><given-names>T</given-names></name><name><surname>Labopin</surname><given-names>M</given-names></name><name><surname>Di Gioia</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: A retrospective study of the EBMT Autoimmune Disease Working Party</article-title>. <source>Blood</source> <year>2011</year>; <volume>118</volume>: <fpage>1693</fpage>–<lpage>1698</lpage>.</citation></ref>
<ref id="bibr56-0961203313479839"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loh</surname><given-names>Y</given-names></name><name><surname>Oyama</surname><given-names>Y</given-names></name><name><surname>Statkute</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used</article-title>. <source>Blood</source> <year>2007</year>; <volume>109</volume>: <fpage>2643</fpage>–<lpage>2648</lpage>.</citation></ref>
<ref id="bibr57-0961203313479839"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bohgaki</surname><given-names>T</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><name><surname>Koike</surname><given-names>T</given-names></name></person-group>. <article-title>Multiple autoimmune diseases after autologous stem-cell transplantation</article-title>. <source>N Engl J Med</source> <year>2007</year>; <volume>357</volume>: <fpage>2734</fpage>–<lpage>2736</lpage>.</citation></ref>
<ref id="bibr58-0961203313479839"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McKendry</surname><given-names>RJ</given-names></name><name><surname>Huebsch</surname><given-names>L</given-names></name><name><surname>Leclair</surname><given-names>B</given-names></name></person-group>. <article-title>Progression of rheumatoid arthritis following bone marrow transplantation: A case report with a 13-year follow-up</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>1246</fpage>–<lpage>1253</lpage>.</citation></ref>
<ref id="bibr59-0961203313479839"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tapprich</surname><given-names>C</given-names></name><name><surname>Fenk</surname><given-names>R</given-names></name><name><surname>Schneider</surname><given-names>P</given-names></name><name><surname>Bernhardt</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>R</given-names></name><name><surname>Kobbe</surname><given-names>G</given-names></name></person-group>. <article-title>Early recurrence of rheumatoid arthritis after nonmyeloablative allogeneic blood stem cell transplantation in a patient with multiple myeloma</article-title>. <source>Bone Marrow Transplant</source> <year>2003</year>; <volume>32</volume>: <fpage>629</fpage>–<lpage>631</lpage>.</citation></ref>
<ref id="bibr60-0961203313479839"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marmont</surname><given-names>AM</given-names></name><name><surname>Gualandi</surname><given-names>F</given-names></name><name><surname>Van Lint</surname><given-names>MT</given-names></name><name><surname>Bacigalupo</surname><given-names>A</given-names></name></person-group>. <article-title>Refractory Evans’ syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus autoimmunity effect</article-title>. <source>Bone Marrow Transplant</source> <year>2003</year>; <volume>31</volume>: <fpage>399</fpage>–<lpage>402</lpage>.</citation></ref>
</ref-list>
</back>
</article>